Zimmer Biomet shares drop almost 4% after reversing from early gains despite Q3 beat and raised guidance
Zimmer Biomet Holdings Inc (ZBH) fell 3.99% as price action reversed after an initial positive gap, even as its stronger-than-expected Q3 earnings and raised guidance created a fundamentally positive backdrop. The pullback contradicts the broadly bullish technical structure, with ZBH trading above all major moving averages in a tight corridor.
Highlights
- Zimmer Biomet reported Q3 2026 net sales of $2.063 billion, a 3.1% year-over-year increase with adjusted EPS of $1.90.
- GAAP diluted EPS declined 13.8% on higher expenses and softness in the knee segment, but management raised full-year sales growth and adjusted EPS guidance.
- Zimmer Biomet stock trades near its session low after an initial gap up, with technical indicators suggesting ongoing strength but overbought conditions and a projected five-day range of $96.75 to $114.77.
Mixed growth offsets knee weakness as guidance and highs meet selling
Zimmer Biomet reported Q3 2026 net sales of $2.063 billion, representing a 3.1% rise year-over-year. Adjusted earnings per share were $1.90, slightly ahead of analyst forecasts, while GAAP diluted EPS fell 13.8% due to increased expenses and softness in the knee segment. Growth in hips, S.E.T., and technology helped offset knee declines, and management raised both full-year sales growth and adjusted EPS guidance. Free cash flow improved and the stock marked a new 52-week high, though price action has remained under broader selling pressure.
Overbought signals flag correction risk as momentum retreats intraday
Zimmer Biomet is positioned above its 20-day, 50-day, and 200-day moving averages at $95.65, $94.9, and $91.84, confirming a bullish structure across short-, medium-, and long-term horizons. Immediate technical resistance stands at $111, with key support at $105.55, delineating a narrow trading range. Momentum remains strong, as MACD and ADX both register buy signals. RSI, Stochastic RSI, and CCI are all in the overbought zone, signaling heightened risk of a short-term correction or overheating. The Bull/Bear Power is positive at 14.57, highlighting buyer dominance in intraday action. The Awesome Oscillator backs the ongoing buying trend. Recent trading saw a reversal lower toward session lows despite an earlier upside gap, with volatility marked at 5.16%. Upward momentum has come under pressure after the open, indicating retreat from intraday highs, even as long-term signals remain constructive.
Previously it was reported that Zimmer Biomet’s bullish chart structure and earnings-driven momentum indicated strong potential for further upside. The current article adds a new dimension by highlighting the possibility of heightened volatility despite robust fundamentals, with immediate attention on the $111 resistance level as a potential catalyst for the next directional move.